INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

The World Journal of Surgical Oncology, published by BMC, is a leading open-access journal that has been disseminating high-quality research since 2003. With an impressive impact, it currently holds a Q2 ranking in Oncology and a Q1 ranking in Surgery for the year 2023, reflecting its significant contribution to the field. Based in the United Kingdom, this journal serves as a vital platform for researchers, clinicians, and students alike, offering comprehensive coverage on topics ranging from innovative surgical techniques to oncology treatment advancements. As part of the esteemed BMC portfolio, the journal leverages a robust editorial process to ensure the publication of impactful research articles that promote a deeper understanding and enhancement of surgical oncology practices. Its commitment to open access ensures that critical research findings are widely accessible, fostering collaboration and knowledge sharing within the global medical community. For those dedicated to advancing their expertise in surgical oncology, the World Journal of Surgical Oncology is an indispensable resource that reflects the forefront of research and clinical practice.

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

BREAST CANCER RESEARCH, published by BMC, is a prestigious open-access journal dedicated to advancing the field of oncology with a specific focus on breast cancer. Since its inception in 1999, the journal has established itself as a leading platform for disseminating high-quality research, with an impressive impact factor and recognition in the Q1 category for both Cancer Research and Oncology as of 2023. The journal is ranked 45th out of 404 in the field of Medicine _ Oncology and 37th out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, placing it in the top echelons of research quality and relevance at 88th and 84th percentiles, respectively. BREAST CANCER RESEARCH is committed to facilitating rapid and open access to groundbreaking findings, making it an invaluable resource for researchers, healthcare professionals, and students striving to enhance their understanding of breast cancer mechanisms, treatments, and prevention strategies. With its base in the United Kingdom, the journal continues to foster international collaborations and discussions aimed at improving patient outcomes and enriching cancer research worldwide.

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, published by BMJ PUBLISHING GROUP, is a leading interdisciplinary journal focused on advancing research and clinical practice in the field of gynecological oncology. With an ISSN of 1048-891X and an E-ISSN of 1525-1438, the journal has established itself as a vital resource since its inception in 1991, covering cutting-edge advancements through 2024 and beyond. The journal holds esteemed rankings, including Q1 in Obstetrics and Gynecology and Q2 in Oncology, highlighting its influence and high citation impact within the medical community. Its Scopus rankings underscore its prominence, placing it among the top 13% of journals in Obstetrics and Gynecology and the top 27% in Oncology. Although it does not currently offer Open Access options, the journal provides a platform for researchers, clinicians, and students to share significant findings and developments that shape the future of gynecological cancer research and treatment. The INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER stands as a significant pillar in the ongoing effort to improve patient outcomes and foster innovation in this critical area of healthcare.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.